Halozyme Therapeutics, Inc. $HALO Stock Holdings Lessened by CW Advisors LLC

CW Advisors LLC reduced its stake in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 12.7% in the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 245,177 shares of the biopharmaceutical company’s stock after selling 35,563 shares during the quarter. CW Advisors LLC owned approximately 0.20% of Halozyme Therapeutics worth $12,754,000 as of its most recent filing with the SEC.

Several other large investors have also recently added to or reduced their stakes in the stock. Wealth Preservation Advisors LLC acquired a new stake in shares of Halozyme Therapeutics during the 1st quarter valued at $32,000. SVB Wealth LLC acquired a new position in shares of Halozyme Therapeutics in the first quarter worth $33,000. Employees Retirement System of Texas purchased a new stake in shares of Halozyme Therapeutics during the second quarter worth $34,000. Brooklyn Investment Group boosted its position in Halozyme Therapeutics by 1,558.1% during the first quarter. Brooklyn Investment Group now owns 713 shares of the biopharmaceutical company’s stock valued at $45,000 after purchasing an additional 670 shares during the last quarter. Finally, Asset Management One Co. Ltd. acquired a new stake in Halozyme Therapeutics during the second quarter valued at $98,000. Institutional investors and hedge funds own 97.79% of the company’s stock.

Analysts Set New Price Targets

Several research analysts have weighed in on the company. Benchmark upped their target price on Halozyme Therapeutics from $75.00 to $90.00 and gave the stock a “buy” rating in a research report on Wednesday, September 24th. Citizens Jmp boosted their target price on shares of Halozyme Therapeutics from $91.00 to $92.00 and gave the stock a “market outperform” rating in a research report on Tuesday, November 4th. Leerink Partnrs upgraded shares of Halozyme Therapeutics from a “strong sell” rating to a “hold” rating in a report on Tuesday, October 14th. Wall Street Zen raised shares of Halozyme Therapeutics from a “buy” rating to a “strong-buy” rating in a research note on Sunday, November 16th. Finally, JMP Securities upped their price objective on shares of Halozyme Therapeutics from $78.00 to $91.00 and gave the stock a “market outperform” rating in a report on Wednesday, August 6th. Seven investment analysts have rated the stock with a Buy rating and seven have given a Hold rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $75.10.

Insider Activity at Halozyme Therapeutics

In other Halozyme Therapeutics news, CFO Nicole Labrosse sold 2,227 shares of the firm’s stock in a transaction that occurred on Monday, September 22nd. The stock was sold at an average price of $77.95, for a total value of $173,594.65. Following the sale, the chief financial officer owned 22,079 shares of the company’s stock, valued at $1,721,058.05. This trade represents a 9.16% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, Director Bernadette Connaughton sold 829 shares of Halozyme Therapeutics stock in a transaction that occurred on Monday, December 1st. The stock was sold at an average price of $71.60, for a total value of $59,356.40. Following the completion of the transaction, the director directly owned 42,123 shares in the company, valued at approximately $3,016,006.80. This represents a 1.93% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 103,625 shares of company stock worth $7,446,727 in the last 90 days. 2.90% of the stock is owned by company insiders.

Halozyme Therapeutics Price Performance

Shares of Halozyme Therapeutics stock opened at $64.66 on Thursday. The company has a current ratio of 1.59, a quick ratio of 1.37 and a debt-to-equity ratio of 1.59. The firm has a fifty day simple moving average of $68.61 and a 200-day simple moving average of $64.20. The stock has a market capitalization of $7.60 billion, a price-to-earnings ratio of 13.61, a PEG ratio of 0.37 and a beta of 0.95. Halozyme Therapeutics, Inc. has a 1-year low of $46.26 and a 1-year high of $79.50.

Halozyme Therapeutics (NASDAQ:HALO) last released its earnings results on Monday, November 3rd. The biopharmaceutical company reported $1.72 earnings per share for the quarter, topping analysts’ consensus estimates of $1.63 by $0.09. The firm had revenue of $354.26 million during the quarter, compared to analyst estimates of $339.18 million. Halozyme Therapeutics had a net margin of 47.91% and a return on equity of 156.95%. The business’s revenue was up 22.1% on a year-over-year basis. During the same quarter in the previous year, the business earned $1.27 EPS. On average, sell-side analysts expect that Halozyme Therapeutics, Inc. will post 4.73 earnings per share for the current year.

Halozyme Therapeutics Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.